leisure time -WSS

leisure time

author：comprehensive 2025-10-02 19:39:17 - browse：4777

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Mass General totes up its waste in a move to tackle climate change

explore

WSS

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Readout Newsletter: Bristol, Sangamo, Gilead, and more

As AI in medicine takes off, can 'human in the loop' prevent harm?

Indian pharmaceutical industry in denial over drug

Amid AI frenzy, a top HHS official's quest to create safeguards

focus

leisure time

explore

Cancer drug shortages should be causing more outrage

Stanford president faces new allegations over 1999 paper

Malaria cases in Florida and Texas: Here’s what you need to know

Vir antibody drug aimed at influenza A fails in clinical trial

Trump demands the U.S. pay no more for drugs than other countries … again

Awakening the world to the whoosh: A patient's crusade

Virginia high school admissions case could be legal follow

Why scientists need input from humanists on sensitive research

Heart attack and stroke risk calculators need revising

Mass General totes up its waste in a move to tackle climate change

explore

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Readout Newsletter: CAR

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Boston's new lab space is opening empty

Ebola: Gilead Sciences antiviral shows promise as new treatment

Steward Health Care Massachusetts hospitals face fiscal disaster

leisure time

explore

focus

hotspot